BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28801846)

  • 1. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study.
    Blaes A; Beckwith H; Florea N; Hebbel R; Solovey A; Potter D; Yee D; Vogel R; Luepker R; Duprez D
    Breast Cancer Res Treat; 2017 Nov; 166(2):541-547. PubMed ID: 28801846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
    Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
    Cardiooncology; 2024 May; 10(1):27. PubMed ID: 38693561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
    Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
    Res Sq; 2023 Apr; ():. PubMed ID: 37066265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer.
    Maor R; Sara JDS; Wanous AA; Maor E; Pruthi S; Lerman A; Sandhu NP
    Coron Artery Dis; 2018 Dec; 29(8):687-693. PubMed ID: 30379695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
    Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
    Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
    Diorio C; Lemieux J; Provencher L; Hogue JC; Vachon E
    Breast Cancer Res Treat; 2012 Nov; 136(2):573-9. PubMed ID: 23053662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
    Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
    Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM; Gligorov J
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychological measures of stress and biomarkers of inflammation, aging, and endothelial dysfunction in breast cancer survivors on aromatase inhibitors.
    Blaes AH; Nair C; Everson-Rose S; Jewett P; Wolf J; Zordoky B
    Sci Rep; 2023 Jan; 13(1):1677. PubMed ID: 36717689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
    Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
    Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
    Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
    Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial.
    Conejo I; Pajares B; Alba E; Cuesta-Vargas AI
    BMC Complement Altern Med; 2018 Jun; 18(1):180. PubMed ID: 29890985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
    Prasad C; Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Bone; 2016 Sep; 90():123-6. PubMed ID: 27018037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Moegele M; Buchholz S; Seitz S; Ortmann O
    Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
    Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
    Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.